Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
We risk forgetting the lessons of the Covid pandemic
Better awareness and access are needed to rebuild measles vaccination rates
A trial of $3 payments for getting a Covid jab in rural Ghana offers a game-changing way to meet public health goals
Americans’ interest in vaccinations has flagged despite efforts to boost uptake of latest jab
Vaccine recipient claims he suffered side effect of severe blood clot
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Biotech blames weaker US sales after lowering full-year forecast
Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Combined jab as effective as separate shots in early stage tests
Companies have yet to provide investors with convincing post-pandemic strategies
Oxford university shot expected to deliver ‘sufficient’ supply for all at-risk infants
Katalin Karikó and Drew Weissman praised for role in ‘unprecedented rate of development’ of coronavirus jabs
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
At least three descendants of Omicron have scientists on alert and vaccination programmes speeding up
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Preliminary studies find exposure to prevalent XBB.1.5 strain elicits antibodies to BA.2.86
Potential mutations prompts authorities to begin immunisation rollout in September
As vaccines are tweaked while new sub-variants emerge, the virus cannot be treated yet as a seasonal bug
